Extended use of tamoxifen reduces breast cancer recurrence and death

Ipilimumab and BRAF inhibitors for advanced melanoma

Effect of metformin on cancer risk and mortality

PDL1 inhibitors in melanoma

Ten years of tamoxifen superior to five in reducing breast cancer recurrence and death

Sorafenib stalls growth of treatment-resistant differentiated thyroid cancer

No survival benefit to adding bevacizumab to standard first-line chemoradiation for glioblastoma

Bevacizumab extends survival for relapsed and advanced cervical cancer

Comment on drug developments in advanced melanoma

Brentuximab vedotin in the frontline setting

Lapatinib in combination with chemotherapy in breast cancer

Cetuximab superior to bevacizumab for advanced colorectal cancer